Shares That Hit Circuit Limits On April 17, 2025, Emcure Pharmaceuticals, Gensol Engineering, and More

On April 17, 2025, BSE Sensex closed 1.96% higher at 78,553.21, while Nifty50 jumped 1.77% to 23,851.65. Amidst the market volatility, stocks like Gensol Engineering, Sky Gold and Diamonds, Emcure Pharmaceuticals, and Kesoram Industries hit circuit limits, reflecting significant price movements. Check out the full list of stocks hitting circuit today.

Stocks That Hit Upper Circuit on April 17, 2025

Stocks That Hit Lower Circuit on April 17, 2025

Overview of Companies Hitting Circuits Today

• Emcure Pharmaceuticals

On April 17, 2025, Emcure Pharmaceuticals share price ended 9.38% higher at ₹1,102.90. Emcure Pharmaceuticals share price reached a 52-week high of ₹1,577.50, and a 52-week low of ₹890.00.

• Tembo Global Industries

On April 17, Tembo Global Industries share price ended 5% lower at ₹427.45. Tembo Global Industries share price reached a 52-week high of ₹905.00, and a 52-week low of ₹191.35. At the current price, Tembo Global Industries shares are trading at a price-to-earnings (P/E) ratio of 12.18x, based on its trailing 12-month earnings per share (EPS) of ₹18.19, and a price-to-book (P/B) ratio of 7.82, according to exchange data.

• Gensol Engineering

On April 17, Gensol Engineering share price ended 5% lower at ₹116.45. Gensol Engineering share price reached a 52-week high of ₹1,125.75, and a 52-week low of ₹116.45. At the current price, Gensol Engineering shares are trading at a price-to-earnings (P/E) ratio of 3.47x, based on its trailing 12-month earnings per share (EPS) of ₹33.85, and a price-to-book (P/B) ratio of 0.69, according to exchange data.

• Panacea Biotec

On April 17, Panacea Biotec share price ended 5% higher at ₹522.95. Panacea Biotec share price reached a 52-week high of ₹522.95, and a 52-week low of ₹112.70. At the current price, Panacea Biotec shares are trading at a price-to-earnings (P/E) ratio of -757.90x, based on its trailing 12-month earnings per share (EPS) of ₹-0.69, and a price-to-book (P/B) ratio of 10.12, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.